Table 1.

Targeting mammalian target of rapamycin (mTOR) sensitizes primary patient-derived acute myeloid leukemia (AML) blasts (AML-IEO20) to LSD1 inhibition. Degree of leukemic cells infiltration of the spleen, bone marrow and surrounding muscular tissues harvested from NSG mice transplanted with human primary AML-IEO20 cells, sacrificed 15 days after initiation of treatment.

Table 1.